Recent studies have found that FABP4 specific inhibitor BMS309403 not only significantly reduces tumor burden in a syngeneic orthotopic mouse model but also increases the sensitivity of cancer cells toward carboplatin (Mukherjee et al., 2020). Here, FABP4 is linked to cancer.